Literature DB >> 23270673

Plasma visfatin, associated with a genetic polymorphism -1535C>T, is correlated with C-reactive protein in Chinese Han patients with traumatic brain injury.

Jian-Feng Weng1, Jun Chen, Wei-Cong Hong, Li-Feng Luo, Wei Yu, Shi-Da Luo.   

Abstract

Visfatin is a newly identified pro-inflammatory adipokine and a genetic polymorphism -1535 C>T located in the visfatin gene promoter has been suggested to be associated with the regulation of visfatin expression in some inflammatory illness. However, there were some conflicting results regarding whether this variant is functional or not. This study aimed to examine the relations of the -1535 C>T single nucleotide polymorphism (SNP) of visfatin gene to the plasma visfatin and C-reactive protein concentrations in traumatic brain injury (TBI). 318 Chinese Han patients with TBI were recruited in this study. Plasma visfatin and C-reactive protein levels were significantly different between the genotypes in the SNP-1535 C>T even after adjustment for age, sex and body mass index. The genotype C-C had the highest plasma visfatin and C-reactive protein concentrations. The plasma visfatin and C-reactive protein concentrations between the variant genotypes C-T and T-T did not differ significantly. Plasma visfatin level was significantly associated with plasma C-reactive protein level using multivariate linear regression. Thus, the SNP-1535 C>T of visfatin gene seemed to be potentially involved in the inflammatory component of TBI through a decreased production of visfatin.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23270673     DOI: 10.1016/j.peptides.2012.12.017

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  4 in total

1.  Visfatin expression and genetic polymorphism in patients with traumatic brain injury.

Authors:  Hong Xiao; Ming Cheng; Li-Jun Zhang; Ke Liu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population.

Authors:  Zhitong Wu; Yifan Sun; Yiyong Huang; Shengbo Zhu; Yi Feng; Huifen Ye; Chunming Liu; Shifu Tang
Journal:  Oncotarget       Date:  2016-11-22

Review 3.  Targeting NAMPT as a therapeutic strategy against stroke.

Authors:  Shu-Na Wang; Chao-Yu Miao
Journal:  Stroke Vasc Neurol       Date:  2019-04-05

4.  Accelerated cardiovascular risk after viral clearance in hepatitis C patients with the NAMPT-rs61330082 TT genotype: An 8-year prospective cohort study.

Authors:  Ming-Ling Chang; Yu-Sheng Lin; Ming-Yu Chang; Chia-Lin Hsu; Rong-Nan Chien; Cathy Sj Fann
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.